아리바이오, 7조 LO 축포 뒤 남은 관문 '옵션 행사' [현장+]

Aria Biotech's 7 trillion won out-licensing agreement with Fusion Pharma represents a strategic victory for Korean biotech in securing global partnerships during clinical development. The option deal structure—with 900 billion won upfront payment and contingent payments post-Phase 3—establishes market-driven valuations for Alzheimer's therapeutics and demonstrates how Korean companies can command competitive leverage for global rights. This transaction highlights the viability of Korean biotech firms in attracting major pharma investments at clinical-stage development.